Advertisement
Dr. Hathaway has previously served as Chief Medical Officer for severaldrug discovery and medical device companies. He has overseen the preclinicaland clinical development of multiple products in the cardiology arena and hasled the strategic development, outlicensing and commercial launch of a numberof pharmaceuticals and medical technologies. He has extensive regulatoryexperience, having served on two successful NDA teams. Moreover, he has ledsuccessful partnering programs for Bristol-Myers Squibb, Knoll, Restoragen andArginox Pharmaceuticals.
Advertisement
Dr. Hathaway was previously Vice President of Medical Affairs with KnollPharmaceutical Company until it was acquired by Abbott Laboratories. While atKnoll he oversaw the Medical Affairs Department and was responsible forclinical research, regulatory affairs, medical information and drug advocacy.Prior to joining Knoll, Dr. Hathaway was Vice President, Cardiovascular DrugDiscovery at Bristol-Myers Squibb, where he managed a team of 90 scientists inthe preclinical development of novel antiarrhythmic and antithrombotic agentsas well as new drugs for heart failure.
Before transitioning to a corporate career, Dr. Hathaway was DivisionChief and Director of the Krannert Institute of Cardiology at the IndianaUniversity School of Medicine, where he practiced for more than 14 years. Healso served as a Clinical Associate and Cardiology Fellow at the NationalInstitutes of Health in Bethesda, Md. While still a practicing clinician heinvented a vascular closure technology which is currently marketed by AbbottVascular as the Closer device and Prostar(R) Suture-Mediated Closure.
Dr. Hathaway has been section editor (Cardiovascular Diseases) of Kelley'sTextbook of Medicine and was a member of the editorial boards of the Journalof Clinical Investigation, the Journal of the American College of Cardiologyand Circulation. He has authored over 80 scientific and medical publicationsand is an inventor on 13 U.S. patents and 8 pending U.S. patent applications.He is a member of the Association of American Physicians, the American Collegeof Physicians and the American Society for Clinical Investigation and is afellow in the American College of Cardiology. He earned his medical degreefrom the Indiana University School of Medicine.
"We are delighted that David will be joining the HeartWare team," saidHeartWare CEO Doug Godshall. "It is rare to find an individual who, after asuccessful career as a physician, has been able to transition seamlessly intothe business world. David's clinical trial management experience, his broadstrategic perspective and his intimate knowledge of the management of heartfailure patients will add tremendous value to HeartWare.
"David will be taking over clinical and regulatory responsibility in Junefrom Jennifer Foley, who will be transitioning out of the company. Jenniferhas for some time expressed a desire to step back in order to spend more timewith her family. She has been committed to completing the setup of our U.S.trial infrastructure and has worked diligently to ensure that we are wellpositioned to begin enrolling patients in the U.S. as soon as we receive FDAapproval of our IDE. Jennifer has been a stellar member of the team and wewish her well."
About HeartWare
HeartWare develops and manufactures miniaturized implantable heart pumps,or Left Ventricular Assist Devices, designed to treat patients suffering fromadvanced heart failure. The Company is developing the industry's smallest andleast invasive pumps, which it believes will be the key to unlocking thepotential of a large and underserved market. The HeartWare(R) LVAS is af
